Takeda Accelerates Digital Transformation with Accenture and AWS

Collaboration will leverage cloud and data-driven insights to accelerate drug development, increase operational agility, reduce technology costs and develop the workforce of the future

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”), Accenture (NYSE: ACN) and Amazon Web Services, Inc. (AWS) have entered into a five-year strategic agreement to accelerate Takeda’s digital transformation.

Not only will patients benefit from Takeda’s ability to respond with greater speed, agility, and insights across the value chain, but customers, employees, and partners will also benefit. This long-term collaboration will fuel Takeda’s cloud-driven business transformation by modernizing platforms, accelerating data services, establishing an internal engine for innovation, and equipping Takeda’s employees with new skills and ways of working.

“By combining the power of three organizations, Takeda is making a bold move to be at the intersection of human health, technology and business growth,” said Christophe Weber, Takeda president and chief executive officer. “My vision is

Read More
Read More

Arrowhead’s New Deal With Takeda Strengthens The Company’s Value Proposition (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (ARWR) is a long-term holding of mine that just recently announced a partnership deal with Takeda (NYSE:TAK) for its ARO-AAT developmental stage therapy. I love this deal and think it yet again shows how well management is strategically and efficiently advancing an impressive pipeline through clinical development.

Arrowhead’s Deal with Takeda is a Win-Win for the Company

On October 8, Arrowhead announced that it had struck a deal with Takeda to co-develop and co-commercialize ARO-AAT, the company’s developmental therapy to treat alpha-1 antitrypsin-associated liver disease (AATLD). The partners will split US profits 50/50, and Takeda received an exclusive license to the therapy in the rest of the world for which Arrowhead will receive 20-25% royalties on net sales.

In exchange for this deal, Takeda is paying Arrowhead $300 million upfront and up to $740 million more in various potential developmental, regulatory, and commercial milestone payments.

I described the

Read More
Read More